**Development of predicted environmental concentrations to prioritize the occurrence of pharmaceuticals in rivers from Catalonia**

Cristian Gómez-Canela

Víctor Pueyo

Carlos Barata

Sílvia Lacorte

Rosa Maria Marcé

Abstract

The main objective of the present study is to prioritize those pharmaceuticals that have higher chances to be detected in water due to incomplete removal in Wastewater Treatment Plants (WWTPs). To do so, the total consumption of pharmaceuticals in Catalonia (NE Spain) were compiled to calculate the predicted environmental concentrations (PECs) in wastewater effluents and in river water. PECs were estimated using publicly available consumption data in the period of 2013–2016 for a suite of 165 compounds. The selected compounds were based on generic pharmaceuticals with emphasis on drugs consumed by people aged 65 or over as they represent the age group with the highest consumption of pharmaceuticals. The mean total consumption of pharmaceuticals in the period studied was of 623 ± 3 t per year. Paracetamol, metformin and ibuprofen were the most administered drugs although the highest PEC values corresponded to metformin, amoxicillin and metamizole. Finally, predicted environmental levels together with acute and chronic toxicological data allowed estimating the risks of these compounds. Amoxicillin is expected to pose adverse effects for cyanobacteria, whereas metformin and ibuprofen pose a small potential for adverse effects to invertebrates and fish, respectively.

1. Introduction

Nowadays, water pollution represents one of the most serious ecological threats we face. Hence, quality of water has to be preserved to protect the environment and human health from compounds capable of exerting an effect at low levels of concentration. Among other chemicals, pharmaceuticals represent nowadays a relevant class of contaminants because they are continuously released into the aquatic environment and are considered as ‘pseudo-persistent’ pollutants (Daughton, 2003; Kümmerer, 2009). The first findings of pharmaceuticals in the aquatic environment were reported in the seventies, where the presence of drugs and drug metabolites were detected in sewage water effluent (Hignite and Azarnoff, 1977). Since then, the recurrent and global occurrence of pharmaceuticals in wastewater treatment plants (WWTPs) and surface waters (river, seas, lakes) is reported in the range of ng L−1 and μg L−1 (Hernando et al., 2006; Kümmerer, 2001; Navarro-Ortega et al., 2012a; Navarro-Ortega et al., 2012b; Ternes et al., 2001). Human consumption, animal use, waste disposal and/or manufacturing are the main sources of pharmaceuticals to the environment (Daouk et al., 2015).

Regarding human consumption, the drugbank has 11,901 drugs in its database (Wishart et al., 2018) and the European Medical Agency (EMA) compiles around 2500 active ingredients. Consumption of pharmaceuticals by the global population varies among countries and its use is expected to grow as the population ages and upon polimedication. Virtually every country in the world is experiencing growth in the number and proportion of the elder population. In 2017, 962 million people aged 60 or over were estimated at a global scale, comprising 13% of the global population, and raising to 25% in Europe. This age group is growing at a rate of about 3% per year (United Nations (UN), 2015). Elder population in developed countries have a high consumption of pharmaceuticals (Valderrama Gama et al., 1998), Typical consumption of 5–10 pills/patient/day in residents of senior residences which is translated in a total consumption of pharmaceuticals of hundreds of milligrams per day/person (Lacorte et al., 2017).

Because monitoring of all pharmaceuticals consumed is practically impossible in terms of time and cost, prioritization tools are needed for compounds that deem to pose negative effects in the environment. Predicted environmental concentrations (PECs) is a practical way (Carballa et al., 2008; Franquet-Griell et al., 2015), to estimate the concentrations of drugs expected to be found in the environment based on consumption data. Its use has been reported before for cytostatic (Franquet-Griell et al., 2015; Franquet-Griell et al., 2017) and other drugs (Burns et al., 2018; Guo et al., 2016; Verlicchi et al., 2014) in wastewater and surface waters.

On the other hand, many pharmaceuticals have been reported to be acutely and chronically toxic to aquatic biota with effects varying largely across taxa and among chemical groups (Crane et al., 2006; Fent et al., 2006a; Overturf et al., 2015; Owen et al., 2007; Santos et al., 2010). Acute toxicity values (immobilization or mortality, algae growth within 48–96 h and the half-maximum effective concentration or lethal concentration, EC50/LC50, value) of pharmaceuticals to algae, aquatic plants, Daphnia magna and fish species have been generally reported in the order of mg L−1. Moreover, in terms of chronic toxicity, most individual pharmaceuticals (such as antibiotics, antibacterial drugs, anti-inflammatory drugs, non-steroidal anti-inflammatory drugs) induce reproductive toxicity in fish and crustaceans at low or environmentally relevant concentrations (ng L−1-μg L−1) (Crane et al., 2006; Fent et al., 2006a; Overturf et al., 2015; Owen et al., 2007; Santos et al., 2010). In addition, the combination of different drugs sharing a common mechanism of action could produce additive effects that would be enough to enhance toxicity (Cleuvers, 2004; Fent et al., 2006b).

Taking into account the large amount and diversity of pharmaceuticals consumed and discharged to the environment, the aim of this study was to prioritize and evaluate their environmental risk by calculating PECs according to the consumption in hospitals and pharmacies from 2013 to 2016. The procedure has been optimized considering Catalonia, a region of 7.5 million inhabitants, with an elderly population (≥65 years) of 24.5%. This region suffers from water scarcity and thus, the levels and potential toxic effects of pharmaceuticals can be high. PECs were calculated in 11 river basins according to specific population distribution and dilution factor (DF). In addition, the potential risk for the aquatic environment was studied considering acute and chronic toxicity of different aquatic taxa for selected pharmaceuticals with highest PECriver.

2. Material and methods

2.1. Consumption data

Consumption data, being the term “consumption” the dispensation or sales of pharmaceuticals, were obtained from Catalan Health Service (CatSalut) over the period 2013–2016 in pharmacies and hospitals. Compound selection was based on medical prescriptions for the elderly (>65 years) in Catalonia in the last years (http://observatorisalut.gencat.cat) (Generalitat de Catalunya - Catalan Health System Observatory, 2018). A total of 165 drugs belonging to 13 different Anatomical Therapeutic Classification (ATC) groups (A, B, C, D, G, H, J, L, M, N, R, S and V) were included. More than 60% of the pharmaceuticals presented in this study are included in the top 200 worldwide sales and prescriptions realized by Njardarson et al. (McGrath et al., 2010; Njardarson, 2010). Table SI1 (Supplementary Information) shows the ATC and the most relevant physico-chemical properties of target compounds. This information does not include consumption through mutual insurance companies, as this data was not available for the public health system. Hospital data was given as the number of pills, capsules or any formulation of each active pharmaceutical ingredient dispensed (called activities). From the composition and the number of activities of each pharmaceutical, the total consumption (in kg year−1) was calculated (Table SI2). The consumptions of the pharmaceuticals in pharmacies were directly provided in mg year−1 by the “Pharmaceutical and Medication Management” of CatSalut.

2.2. PEC calculations (effluent, river and basins)

To calculate the predicted environmental concentrations in WWTP effluents (PECeff) and surface waters (PECriver) in μg L−1, the following equations adapted from Besse et al. (2008) were used:

(1)

(2)

Consumption (g day−1) is the quantity of each pharmaceutical consumed in Catalonia; Fexc is the excreted fraction of the unchanged drug, considering both urine and feces. Values were extracted from the Drugbank database (Wishart et al., 2018). For those drugs whose values could not be found, a default value of 0.5 was applied, considering that a pharmaceutical will not be totally excreted as parental compound; Fwwtp is the removal fraction in WWTP. Here, when no data was obtained from the bibliography, a default value of 0.5 was used. Then, 1-Fwwtp, is the fraction of pharmaceutical's emission from WWTPs to surface waters; W (L inhab−1 d−1) is the mean water consumption per person per day (about 130.9 L inhab−1 d−1 in Catalonia). This value was calculated from the mean total urban water consumption in Catalonia in the period studied and the number of inhabitants (IDESCAT, 2017). Inhab is the number of inhabitants in a defined zone (in Catalonia, a mean value of 7,446,487 during the period of 2013–2016). In the calculation of PECs, there are several uncertainties which are related to the input parameters of the PEC formula. These uncertainties can produce a bias in the PEC calculation and can alter the results obtained, and thus, their applicability. Among all parameters used in the PEC calculation, the two most significant in the variability of the results are: Fexc and Fwwtp. In the case of excretion rate, several publications are available on the metabolism of pharmaceuticals and different excretion factors are reported for each drug. The observed differences are probably explained by genomically distinct metabolizing capacities, as well as differences in the routes of administration, sex, age, and health status of the studied subjects (Wishart et al., 2018). On the other hand, removal rates of pharmaceuticals in WWTPs are largely dependent on hydrophobicity and persistence characteristics of the substances. Persistent hydrophilic substances will be present to a greater extent in the treated liquid effluent, hydrophobic ones in the sludge. Expectable removals in WWTPs can thus be inferred to some extent from the substances degradation rates and Kow or Koc values (Lindim et al., 2016). Removal efficiency values can vary between 10 and 90% and thus, it is important to use the most accurate value in a given site (Estrada-Arriaga et al., 2016; Gros et al., 2017; Gros et al., 2010; Kasprzyk-Hordern et al., 2009; Lajeunesse et al., 2012; Lin et al., 2009; Rosal et al., 2010). The values can be different in WWTP locations according to the served population, capacity, the configuration and type of treatment, in operating parameters and in hydraulic and solid retention times. Other factors such as meteorological conditions, sampling procedure (grab, composite or flow-proportional (Ort et al., 2010) and sampling period (seasonality) can also affect the empirical Fwwtp. In the present study, WWTP removals have been selected following previous published papers, and in the case that no removal values were founded, a 50% of removal was used. Removal efficiencies can range from 9 to 100%.

Finally, DF is the dilution factor used from WWTP effluents to surface waters. Changes in this value can vary the results >100-fold (Franquet-Griell et al., 2017). In 2006, EMA recommended the use of a default value of 10 (EMA, 2006). However, a more accurate value has been proposed considering the dilution factor of each country, and a value of 25 as the median of the DFs for Spain (Keller et al., 2014). Initially, PECriver values in the present study were calculated using this DF.

However, to obtain more accurate PECs, DFs for the main hydrographic basins in Catalonia were calculated to obtain a better representation of the contamination levels, taking into account the specific characteristics of flow and population. Studied basins were Muga and Fluvià, Ter, Besòs, Llobregat, Francolí, Tordera, Ebro, Segre (a tributary of Ebro), and Noguera Pallaresa and Ribagorçana (tributaries of Segre), which cover most of the area. Table 1 shows geographical information of each river studied, including the population, the river basin area, the length, the water use (L/inhab/day) and the mean, minimum and maximum DF calculated. These new DFs were calculated adapting the formula from Keller et al. (2014) (Keller et al., 2014):

(3)

where,

Table 1. Main hydrographic basins in Catalonia (Spain), territory information with population inhabiting in each basin, area, water use and calculated dilution factors (DF) using mean, maximum and minimum flows. All values have been extracted from www.idescat.cat (Statistical Institute of Catalonia (IDESCAT), 2008). \*This length only represents the part of the river along the Catalonia territory.

Population Area Length Water use River flow (m3/s) DF

Inhab. km2 km L/inhab/day Mean Min-max Mean Min-max

Muga 21,195 854 58 231 2 0.1–4 11 1–21

Fluvià 59,099 1125 97 188 7 1–11 26 4–40

Ter 583,673 3010 208 142 17 4–20 18 5–23

Tordera 157,865 894 55 244 5 1–9 10 2–19

Besòs 1,587,862 1038 18 121 4 0.1–16 2 0.05–7

Llobregat 2,090,971 4948 175 129 19 0.2–124 7 0.1–100

Francolí 313,892 838 85 177 1 0.1–5 2 0.2–8

Ebre 180,855 3340 120\* 159 173 150–199 521 452–600

Segre 211,772 22,579 265 143 16 12–22 32 24–43

Noguera Ribagorçana 96,252 2046 133 163 9 8–11 50 42–61

Noguera Pallaresa 31,125 2820 154 223 19 17–24 237 218–304

Qr (m3/s) is the river flow of each river. The flow data were collected from the hydrographic confederations of each basin and considered geographic and seasonal variability along the basin. Maximum, minimum and mean river flows were used to better estimate PEC variability. The flow data reflect the withdrawal of water in each area. Inhabbasin is the population in the basin area (inhabitants). Wbasin is the water use per capita in the basin, including domestic and industrial use (m3 inhab−1 year−1). If data was not available, water consumption at national scale (130 m3 inhab−1 year−1) was used. 31,536,000 are seconds per year used to convert units.

To calculate PECriver for each basin, the DF derived from high, mean and low flows in each river basin were applied to Eq. (1) and consumption of pharmaceuticals was considered to be proportional to the population in the studied area. Finally, the ∑PECriver considering each individual drug represented the global occurrence of these compounds in each basin.

2.3. Acute toxicity and environmental risk assessment (ERA)

The acute toxicity of the prioritize pharmaceuticals was reported from the bibliography. However, in the case of metformin, the acute toxicity was determined in the crustacean Daphnia magna following standardized protocols (Organization of Economic Co-operation and Development (OECD) 1981) according to Gómez-Canela et al. (2014). Exposure concentrations were prepared in American Society for Testing Materials (ASTM) water at 20 °C using acetone as a carrier (0.1 mL L−1). Negative controls (no acetone) and acetone controls gave no response. Aging of ASTM water was conducted in the laboratory at 20 °C in the darkness to prevent photolysis. Assays were conducted in 50 mL of test medium with 10 animals, per duplicate, and were started at <24-h-old neonates and ended at 48 h. Lethal median concentration effects were estimated fitting immobility concentration responses to the Hill regression model.

After calculating PECs in surface water (PECriver), risk assessment was performed to determine if these predicted concentrations could cause hazard in the aquatic environment. The guidelines recommends performing a risk assessment when PECriver are higher than 0.01 μg L−1 (EMA, 2006). Herein, ERA has been calculated for pharmaceuticals with PECriver values higher than 0.2 μg L−1 in 2016 because of the low toxicity of pharmaceuticals with PECriver values between 0.01 and 0.2 μg L−1. The risk quotient (RQ) was calculated using the following equation (Eq. (4)), depending on the available data (Gómez-Canela et al., 2014):

(4)

where, PEC is the predicted concentration for a specific basin only in 2016 (described in the previous section) and PNEC is the predicted no-effect concentration. PNEC was estimated using the chronic toxicity NOEC (no-observed effect concentration) and a security factor ƒ1 of 10 (OECD, 2002). If NOEC was not available, we took LOEC values as a NOEC proxy. When chronic toxicity NOEC/LOEC were not available, PNEC were estimated using E(L)C50, and a security factor ƒ2 of 1000 (OECD, 2002). For metformin, experimental acute toxicity results in Daphnia magna and zebrafish embryos were obtained following existing guidelines OECD 202 (OECD, 2004) and OECD 236 (OECD, 2013) used to estimate PNEC. For data interpretation, the maximum probable risk for ecological effects from contaminated water was followed as recommended by Wentsel et al. (1996):

RQ < 1.0 indicates no significant risk;

1.0 ≤ RQ < 10 indicates a small potential for adverse effects;

10 ≤ RQ < 100 indicates significant potential for adverse effects;

RQ ≥ 100 indicates that potential adverse effects should be expected.

3. Results and discussion

3.1. Consumption of pharmaceuticals: the case study of Catalonia

The mean total consumption of 165 pharmaceuticals in the four years studied (2013–2016) was 623 ± 3 t per year (Table SI2). In 2013, the total consumption of these pharmaceuticals was 599 t year−1, increasing up to 638 t year−1 in 2016, showing a 6.5% increase. ATC groups N (nervous system), A (alimentary tract and metabolism) and M (musculo-skeletal system) showed the highest consumptions with values between 47 and 318 t year−1 respectively. Fig. 1 displays the consumption trends for all pharmaceuticals compiled ordered by their ATC codes from high to low values. Analyzing the period 2013–2016, the pharmaceuticals belonging to ATC groups N, A, J, H and G have increased their consumption in 2016 with respect to 2013. However, the pharmaceuticals belonging to ATC groups M, S, R and L decreased their consumption in 2016 regard to 2013 (see Fig. 1).

Fig. 1. Consumption of pharmaceuticals (in t year−1) ordered by their ATC codes.

A- Alimentary tract and metabolism: The 24 pharmaceuticals for which consumption data was requested had a mean total annual consumption of 182 t year−1 (Table SI2). Metformin, the first-line medication for the treatment of type 2 diabetes, is the most consumed drug in this family with levels between 156 and 164 t year−1, increasing its consumption along the years. The next most consumed drugs were lactulose, omeprazole and ranitidine with levels from 2.3 to 11 t year−1 (Table SI2). The other compounds were consumed at levels <2 t year−1. Many of these drugs are consumed by the elderly population.

B- Blood and blood forming organs: In this group, the 11 drugs showed a slight decreasing consumption from 18.8 to 17.4 t year−1 was observed (Fig. 1). Acetylsalicylic acid (also known as aspirin) is a medication used to treat pain, fever, or inflammation and was consumed up to 15.9 t year−1 (Table SI2). It was followed by clopidogrel, tranexamic acid and ferrous glycine sulfate. The consumptions of these drugs varied from 0.6 (in 2013) to 1.5 t (in 2016). The remaining seven drugs were below 0.19 t in 2016 (Table SI2).

C- Cardiovascular system: Thirty different drugs administered in Catalonia had a mean total annual consumption of 28.6 t. The highest consumptions in this ATC group corresponded to pentoxifylline, valsartan, simvastatin, enalapril, hydrochlorothiazide, furosemide, atorvastatin, losartan and atenolol with levels between 1.5 and 6.2 t year−1 in the period studied (see Table SI2). The consumptions remained constant all the period, except for pentoxifylline that decreased from 6.2 t (2013) to 4.5 t (2016), while valsartan and losartan increased their consumptions from 3.2 t (2013) to 5.5 (2016) and from 1.8 t (2013) to 2.2 t (2016), respectively. Herein, the case of furosemide is curious because its values remained slightly constant in the years 2013 (1.8 t), 2014 (1.9 t) and 2016 (2.1 t), but in 2015 its consumption decreased considerably to 0.4 t (Table SI2).

D- Dermatologicals: Among 7 drugs for which consumption data was requested, ketoconazole and clotrimazole were the most consumed pharmaceuticals. Levels in this group were low compared to other ATC groups varied from 0.002 (gentamicin) to 0.32 t year−1 (ketoconazole).

G- Genito urinary system and sex hormones: Only ciproterone, tamusoline and finasteride were the pharmaceuticals compiled for this ATC group. Consumptions increasing along the period studied with values between 0.011 t year−1 and 0.035 t year−1, attributed mainly to finasteride (used for hair loss treatments) which its consumption increased from 27 kg in 2013 up to 36 kg in 2016 (Table SI2). However, overall consumptions are low.

H- Systemic hormonal preparations, excl. sex hormones and insulins: Five different drugs of this ATC group (dexamethasone, methylprednisolone, prednisone, triamcinolone and glucagon) were consumed in Catalonia. The mean total annual consumption of these drugs was 0.3 t in the period studied. The highest consumption was for prednisone, a synthetic corticosteroid used to certain inflammatory diseases and some types of cancer, ranging from 0.24 t in 2013 and 0.29 t in 2016 (see Table SI2).

J- Antiinfectives for systemic use: Twelve drugs belong to this group were dispensed, with consumptions between 30.3 t (in 2013) and 33.5 t (in 2015) (Fig. 1). The slight decreasing between 2015 and 2016 (32.9 t) could be due to the awareness campaign against the inappropriate use of antibiotics promoted by the World Health Organization (WHO) (WHO, 2018). Amoxicillin, used for the treatment of a number of bacterial infections, was the most consumed pharmaceutical accounting for more than the 87% of the total consumption in this ATC group.

L- Antineoplastic and immune modulating agents: Antineoplastic drugs, also called cytostatic drugs, are pharmaceutical used in the cancer treatments. In this study, only megestrol was requested as data for other cytostatics has been previously published (Franquet-Griell et al., 2015; Franquet-Griell et al., 2017). Megestrol, a progestin with antiandrogen activity, is mainly used as an appetite stimulant and sometimes in the treatment of breast and endometrial cancers. Levels of megestrol have been decreasing along the years and its consumption has changed from 0.16 t year−1 in 2013 to 0.11 t year−1 in 2016 (see Table SI2).

M- Musculo-skeletal system: Among 7 drugs for which information was requested, ibuprofen was the pharmaceutical with the highest values followed by allopurinol and diclofenac. The total levels of these 8 drugs were in the range of 64.5 t year−1 (in 2013) decreasing to 47.8 t year−1 (in 2016). In this case, ibuprofen represented approximately the 88% of the total consumption in this ATC group (Table SI2), followed by diclofenac, whose levels decreased considerably along the last years (Table SI2). This lower consumption for ibuprofen in 2016 could be related to the fact that EMA (2014) started to review the cardiovascular risks with systemic ibuprofen medicines (such as those taken by mouth but not topical medicines like creams and gels). The cardiovascular risks being evaluated concern high-dose ibuprofen (2400 mg per day) taken regularly for long periods (EMA, 2014). As in the case of ibuprofen, in 2013, EMA advised the additional risk to suffer heart attacks using diclofenac at high doses (Baigent et al., 2013; EMA, 2013).

N- Nervous system: This ATC group was the one for which more compounds information was requested, as represent the pharmaceuticals administered mostly to the elder population. Total consumptions of 50 compounds increased from 270 t in 2013 up to 319 t in 2016 (Fig. 1). The most consumed pharmaceuticals were paracetamol (201–235 t year−1), metamizole (13.6–20.9 t year−1), gabapentin (10.9–12.1 t year−1), valproic acid (6.7–6.9 t year−1) and levetiracetam (6.4–8.4 t year−1). The other pharmaceuticals studied in this group had levels between 0.09 and 34.47 t year−1.

R- Respiratory system: In this ATC group, the 8 drugs included had consumptions ranging between 0.48 t in 2013 and 0.34 t in 2016 (Table SI2). Theophylline, a methylxanthine drug used in therapy for respiratory diseases such as asthma, was the most consumed drug with a mean value of 0.29 t year−1. In general, lower levels were reported in comparison to other ATC groups.

S- Sensory organs: Chloramphenicol, norfloxacin, dorzolamide, timolol and latanoprost were the most consumed pharmaceuticals. Among those, norfloxacin, a synthetic chemotherapeutic antibacterial agent, was the most consumed with ranges between 0.57 t year−1 (in 2013) and 0.46 t year−1 (in 2016).

V- Various: This group comprises many different types of drugs. In the present study, naloxone and flumazenil have been included. These two drugs were the least consumed group (Table SI2).

3.2. PECs of pharmaceuticals in wastewaters and rivers

PECs were calculated for the target pharmaceuticals administered mainly in the elder population from Catalonia. Two different PECs (in μg L−1) were calculated; PECeff, which represent the estimated levels in WWTP effluents and PECriver, which takes into account the DF from WWTP to surface water and represents the estimated concentration in the rivers. In fact, the value of PEC calculation relies in having precise information on demography, geographical data and water management issues. Using a DF of 25 according to Keller et al. (2014), Table SI3 shows PEC values for 165 pharmaceuticals consumed in Catalonia. Out of 165 drugs, 46 had PECriver > 0.01 μg L−1, which is the EMA threshold value for risk assessment. Low PECs were attributed to compounds with low consumption, poor excretion or high degradability in the WWTPs.

Considering ∑PECs, values ranged between 148 and 162 μg L−1 (PECeff) and between 5.7 and 6.2 μg L−1 (PECriver), observing a slightly increase over the study period. Table 2 shows those drugs with highest PECs obtained (both PECeff and PECriver), including their consumption during the four years (kg day−1), excretion rate (Fexc) and WWTP removal (Fwwtp).

Table 2. Prioritization of pharmaceuticals according to EMA's threshold >0.01 μg L−1 in river. Consumption rates (kg day−1), PECeff and PECriver values (in μg L−1) using a dilution factor of 25 according to Keller et al. (2014) are indicated during the period 2013–2016, and include excretion rates (Fexc) and removal in WWTP (Fwwtp). PECs from all pharmaceuticals are listed in Table SI3. Fexc values were obtained from Drugbank 5.0 database (Wishart et al., 2018) and Fwwtp values were obtained from previous published papers. In the case that Fexc and Fwwtp values were not found, a value of 0.5 were chosen (marked with an asterisk).

ATC code Name Fexc Fwwtp 2013 2014 2015 2016

kg/day PECeff PECriver kg/day PECeff PECriver kg/day PECeff PECriver kg/day PECeff PECriver

A10BA02 Metformin 1 0.9 (Estrada-Arriaga et al., 2016) 429 44 1.68 440 45 1.72 450 46 1.76 455 46 1.79

J01CA04 Amoxicillin 0.8 0.5 83.1 34 1.30 92.5 38 1.45 93.0 38 1.46 91.6 37 1.44

N02BB02 Metamizole 0.5 0.5 37.4 10 0.37 45.1 11 0.44 51.5 13 0.51 58.2 15 0.57

N03AX14 Levetiracetam 0.66 0.5 17.5 5.9 0.23 19.5 6.5 0.25 21.4 7.2 0.28 23.3 7.8 0.30

N03AX12 Gabapentin 0.5\* 0.85 (Lin et al., 2009) 30.1 4.6 0.18 32.3 4.9 0.19 33.2 5.1 0.20 33.7 5.1 0.20

C04AD03 Pentoxifylline 1 0.23 (Kasprzyk-Hordern et al., 2009) 16.9 6.9 0.27 15.2 6.2 0.24 13.7 5.6 0.22 12.6 5.1 0.20

N03AX16 Pregabalin 0.9 0.5 7.6 3.5 0.13 8.1 3.7 0.14 8.3 3.8 0.15 8.6 3.9 0.15

A02BC01 Omeprazole 0.23 0.09 (Rosal et al., 2010) 14.7 3.1 0.12 14.7 3.1 0.12 14.3 3.0 0.12 14.0 3.0 0.11

N04BA02 Levodopa 0.5\* 0.53 (Rosal et al., 2010) 7.9 2.0 0.08 8.3 2.1 0.08 8.6 2.2 0.08 8.8 2.2 0.09

N05AN01 Lithium 0.5\* 0.5 7.7 2.0 0.08 7.9 2.0 0.08 7.9 2.0 0.08 8.0 2.0 0.08

A11CC05 Cholecalciferol 0.5\* 0.5 4.5 1.1 0.04 0 0 0 0 0 0 7.5 1.9 0.07

M04AA01 Allopurinol 0.2 0.5 17.1 1.7 0.07 17.6 1.8 0.07 17.6 1.8 0.07 17.3 1.8 0.07

N01BB02 Lidocaine 0.5\* 0.5 2.3 0.6 0.02 3.6 0.9 0.03 5.0 1.3 0.05 6.7 1.7 0.07

J01MA02 Ciprofloxacin 0.5\* 0.55 (Wishart et al., 2018) 6.9 1.6 0.06 6.5 1.5 0.06 6.5 1.5 0.06 6.4 1.5 0.06

J01MA12 Levofloxacin 0.9 0.5 2.6 1.2 0.05 2.9 1.3 0.05 3.1 1.4 0.05 3.0 1.4 0.05

C03AA03 Hydrochlorothiazide 0.5\* 0.53 (Gros et al., 2017) 6.1 1.5 0.06 6.0 1.4 0.06 5.8 1.4 0.05 5.6 1.3 0.05

N02AX02 Tramadol 0.3 0.4 (Lin et al., 2009) 6.3 1.1 0.04 6.9 1.2 0.05 7.1 1.3 0.05 7.1 1.2 0.05

N06AX05 Trazodone 0.5\* 0.5 3.9 1.0 0.04 4.2 1.1 0.04 4.5 1.1 0.04 4.8 1.2 0.05

C03CA01 Furosemide 0.9 0.74 (Estrada-Arriaga et al., 2016) 5.1 1.1 0.04 5.4 1.1 0.04 1.2 0.2 0.01 5.7 1.2 0.05

M01AE01 Ibuprofen 0.1 0.91 (Rosal et al., 2010) 151 1.4 0.05 146 1.3 0.05 121 1.1 0.04 111 1.0 0.04

C09CA01 Losartan 0.35 0.5 4.8 0.8 0.03 5.2 0.9 0.04 5.4 1.0 0.04 5.6 1.0 0.04

N03AX11 Topiramate 0.7 0.5 2.6 0.9 0.04 2.6 0.9 0.04 2.6 0.9 0.04 2.6 0.9 0.04

B01AC04 Clopidogrel 0.5 0.5 4.0 1.0 0.04 3.9 1.0 0.04 3.7 0.9 0.04 3.6 0.9 0.03

C07AB03 Atenolol 0.5\* 0.59 (Rosal et al., 2010) 4.6 1.0 0.04 4.5 0.9 0.04 4.3 0.9 0.03 4.0 0.8 0.03

B01AC06 Acetylsalicylic acid 0.5\* 0.96 (Gros et al., 2010) 43.6 0.9 0.03 42.5 0.9 0.03 41.5 0.8 0.03 40.5 0.8 0.03

A02BA02 Ranitidine 0.3 0.66 (Rosal et al., 2010) 6.3 0.7 0.03 6.4 0.7 0.03 6.6 0.7 0.03 6.8 0.7 0.03

N05CM02 Clomethiazole 0.5\* 0.5 2.4 0.6 0.02 2.6 0.7 0.03 2.7 0.7 0.03 2.7 0.7 0.03

D11AX18 Diclofenac 0.65 0.58 (Lajeunesse et al., 2012) 4.2 1.2 0.05 3.2 0.9 0.03 2.6 0.7 0.03 2.3 0.6 0.03

A10BB09 Gliclazide 0.35 0.5 2.8 0.5 0.02 3.0 0.5 0.02 3.3 0.6 0.02 3.4 0.6 0.02

C01BD01 Amiodarone 0.5\* 0.5 2.3 0.6 0.02 2.4 0.6 0.02 2.4 0.6 0.02 2.3 0.6 0.02

C10AA01 Simvastatin 0.13 0.5 9.4 0.6 0.02 9.4 0.6 0.02 9.2 0.6 0.02 8.8 0.6 0.02

A07AA11 Rifaximin 0.95 0.5 0.7 0.3 0.01 0.8 0.4 0.02 1.0 0.5 0.02 1.2 0.6 0.02

B03AA01 Ferrous glycine sulfate 0.5\* 0.5 1.6 0.4 0.02 1.9 0.5 0.02 1.8 0.5 0.02 1.9 0.5 0.02

M01AE17 Dexketoprofen 0.8 0.5 0.9 0.4 0.01 0.9 0.4 0.01 1.0 0.4 0.02 1.0 0.4 0.02

B02AA02 Tranexamic acid 0.5\* 0.5 1.5 0.4 0.01 1.5 0.4 0.02 1.6 0.4 0.02 1.6 0.4 0.02

A06AD11 Lactulose 0.03 0.5 30.1 0.5 0.02 27.8 0.4 0.02 25.0 0.4 0.01 26.1 0.4 0.02

N06AB03 Fluoxetine 0.5\* 0.36 (Gros et al., 2010) 1.2 0.4 0.01 1.2 0.4 0.01 1.2 0.4 0.01 1.2 0.4 0.01

N05BA01 Diazepam 0.5\* 0 (Kasprzyk-Hordern et al., 2009) 0.7 0.3 0.01 0.7 0.4 0.01 0.7 0.4 0.01 0.7 0.4 0.01

C07AA05 Propranolol 0.5\* 0.33 (Lin et al., 2009) 0.9 0.3 0.01 0.8 0.3 0.01 0.8 0.3 0.01 0.9 0.3 0.01

N06AB04 Citalopram 0.23 0.27 (Gros et al., 2010) 1.8 0.3 0.01 1.9 0.3 0.01 1.9 0.3 0.01 1.8 0.3 0.01

N06AX16 Venlafaxine 0.05 0.19 (Gros et al., 2010) 6.8 0.3 0.01 7.0 0.3 0.01 7.1 0.3 0.01 7.2 0.3 0.01

N07BB01 Disulfiram 0.5\* 0.5 1.1 0.3 0.01 1.2 0.3 0.01 1.1 0.3 0.01 1.2 0.3 0.01

N05AH02 Clozapine 0.5 0.5 0.9 0.2 0.01 1.0 0.2 0.01 1.0 0.3 0.01 1.1 0.3 0.01

N03AB02 Phenytoin 0.5\* 0.44 (Lajeunesse et al., 2012) 1.1 0.3 0.01 1.1 0.3 0.01 1.0 0.3 0.01 0.9 0.3 0.01

Values of predicted concentrations for each drug are explained below, described from higher to lower PEC and according to temporal trends for each compound. In the period analyzed (2013–2016), the pharmaceuticals with highest estimated concentrations in the WWTP effluents and consequently in rivers were metformin, amoxicillin, metamizole, levetiracetam, pentoxifylline and gabapentin, with levels between 5.1 and 46 μg L−1 (PECeff) and between 0.20 and 1.79 μg L−1 (PECriver) in 2016 (see Table 2).

Fig. 2 displays the maximum, minimum, the 75% quartile and the 25% quartile of the PECeff (μg L−1) of all pharmaceuticals evaluated. Only the data of 2016 has been represented because the profiles of the other years are similar. The 6 drugs with the highest PECs and which should be prioritized in monitoring studies are described below.

Fig. 2. Boxplot in logarithmic scale of pharmaceuticals PECeff levels in 2016 for each ATC family. The rest of the years studied have not been represented because they have similar profiles. N indicates the number of pharmaceuticals studied in each family.

Metformin, a first-line medication for the treatment of type 2 diabetes, was a highly consumed drug with the highest PEC values. The PECeff and PECriver were constant among the period 2013–16, ranging from 43.6 to 46.2 μg L−1 and from 1.68 to 1.78 μg L−1, respectively (Table 2). It has a high excretion rate of 100% (Wishart et al., 2018) and WWTP removal of 94% (Estrada-Arriaga et al., 2016). Little information is available on metformin in waters. Carmona et al. (2017) detected metformin in influent, effluent and river water from Turia River (Spain) at 5.927, 1.252 and 0.013 μg L−1, respectively.

Second, amoxicillin had a consumption slightly increasing in the period 2013–15, but suffered a decrease in 2016. Its maximum PECeff and PECriver were 37.8 μg L−1 and 1.46 μg L−1, respectively in 2016 (Table 2). These values are in the order of the levels of amoxicillin in effluents from Girona WWTP that ranged between 0.216 and 0.258 μg L−1 (Gros et al., 2013).

The following drug with higher values of PEC was metamizole. This pharmaceutical increased its PECeff and PECriver values from 9.5 and 0.36 μg L−1 in 2013 up to 14.8 and 0.57 μg L−1 in 2016, respectively (Table 2). Metamizole, a pharmaceutical used as a painkiller, spasm and fever reliever, is excreted partially (Wishart et al., 2018) and thus, it is expected to be found in aquatic environments. Guedes-Alonso et al. (2013) reported levels of 13 pharmaceuticals in WWTPs from Gran Canaria Island (Spain), detecting concentrations of metamizole between 0.24 and 8.25 μg L−1 (Guedes-Alonso et al., 2013). However, not many studies have published the presence of metamizole in waste and river waters from Spain because its rapid degradation to the metabolite 4-acetamidoantipyrine (Huntscha et al., 2012).

Levetiracetam, a medication used to treat epilepsy, is excreted via urine around a 66% of the total drug consumed (Wishart et al., 2018). Its PECeff and PECriver slightly increased from 5.8 to 7.8 μg L−1 and from 0.23 to 0.30 μg L−1, respectively (Tables 2 and SI3). The presence of levetiracetam in Spanish waters has never been studied. However, this compound was detected in influents and effluents from a WWTP from Dresden (Germany) with a concentrations higher than 1 μg L−1 (Gurke et al., 2015).

Gabapentin, a medication used to treat partial seizures, neuropathic pain, hot flashes, and restless legs syndrome, was estimated in WWTP effluents at concentrations between 4.6 μg L−1 (2013) and 5.1 μg L−1 (2016), and in catalan rivers between 0.17 and 0.20 μg L−1 in the period studied. Gabapentin has also been detected in European rivers at levels of low μg L−1 (Klančar et al., 2018).

Finally, pentoxifylline, is a xanthine derivative used as a drug to treat muscle pain in people with peripheral artery disease and is the 6th drug with the highest PECs. PECs ranged between 5.1 and 6.9 μg L−1 (PECeff), and between 0.20 and 0.27 μg L−1 (PECriver), see Tables 2 and SI3. Pentoxifylline has not been detected in Spanish waters but Vanderford et al. (2003) detected this drug at 0.0022 μg L−1 in waters from Las Vegas (United States).

Other highly consumed drugs had low PEC values because of their high removal efficiency in the WWTPs. This is the case of paracetamol, ibuprofen and acetylsalicylic acid. Paracetamol was the pharmaceutical with highest consumption (Table SI3), however its PEC values were low. Paracetamol can be excreted via urine in a 90% (Wishart et al., 2018) and is completely eliminated in WWTP. Its PECeff ranged from 0.17 and 0.2 μg L−1 in the 2013–2016 period and the PECriver from 0.0065 and 0.0077 μg L−1, following consumption patterns (Table SI3). Many studies have reported the presence of paracetamol in rivers of around the world (Carmona et al., 2017). Paracetamol was detected at mean concentration of 0.98 μg L−1 and with 45.5% detection frequency in a monitoring studied carried out in 2014 along the Guadalquivir River (Jaén, South Spain) (Robles-Molina et al., 2014). In another study, López-Roldán et al. detected paracetamol at 0.034 μg L−1 in the Llobregat River (Catalonia, Spain) (López-Roldán et al., 2010), highly approaching the PECs calculated in this study. Although paracetamol is predicted to be present at very low levels, its high consumption and the high frequency of detection in waters justifies its inclusion in monitoring studies related to water quality. Ibuprofen, a well-known antiinflamatory drug, has a very high consumption (mean = 47.8 t year−1) but taking into account that only 10% is excreted (Wishart et al., 2018), PEC values were low (see Table SI3). Ibuprofen has been recurrently monitored in waste and surface waters (Hedgespeth et al., 2012; Lindberg et al., 2014). In Catalonia, ibuprofen was detected in influent waters (0.172–4.21 μg L−1) and effluent waters (0.03–0.95 μg L−1) from sewage treatment plants (Pedrouzo et al., 2011). Recently, ibuprofen was detected at concentrations up to 2.66 μg L−1 in sites impacted by raw wastewater in Ebro river (Mandaric et al., 2018). In another study, López-Serna et al. studied the occurrence of 95 pharmaceuticals and transformation products in the metropolis of Barcelona, including Besòs River. Authors reported concentrations of ibuprofen at 0.061 μg L−1 (López-Serna et al., 2013). Ibuprofen was also detected in Llobregat river at 0.152 μg L−1 (López-Roldán et al., 2010).

Finally, acetylsalicylic acid had constant PECeff (from 0.89 to 0.82 μg L−1) and PECriver (from 0.034 to 0.032 μg L−1) over the studied period. Acetylsalicylic acid has been detected in water as salicylic acid due to its rapid degradation (Skibinski and Komsta, 2016). In the North Sea, the Scheldt estuary and in Belgian harbours salicylic acid was detected at levels ranging from 0.011 to 0.855 μg L−1 between the period May 2007 and June 2009 (Wille et al., 2010). In another study, salicylic acid was detected in influents and effluents of two WWTPs in Portugal at levels between 1.17 and 61.26 μg L−1 (influents) and between 0.11 and 0.30 μg L−1 (effluents) and in the receiving water of the Lis River at a concentration range of 0.025 to 0.29 μg L−1 (Paíga et al., 2016).

3.3. Application of PECs in hydrographic basins

To obtain more accurate information and due to the important role of DF in the calculation of PECs (Franquet-Griell et al., 2017), DFs were recalculated for the most important hydrographic basin in Catalonia according to the Eq. (3). Mediterranean rivers, are characterized by high flow fluctuations because of seasonal variations linked with the weather and precipitations. Thus, it is important to determine PECs in each river basin considering this flow variability. For that reason, mean flow values from the middle course of the river, and maximum and minimum flows were compiled for each river during 2016 to represent the flow variability (Table 1). Table 3 displays the PECriver ranges in each river basin for these main compounds detected in each basin. To determine the global impact of pharmaceuticals in the different basins, total PECriver (∑PECriver) were calculated considering all compounds using the mean DF of each river basin in 2016. Fig. 3 shows the hydrographic basins studied colored according to their ∑PECriver. Among the eleven main Catalan river basins studied, Noguera Pallaresa and Noguera Ribagorçana, Fluvià, Segre and Ebro River (only the part of the river in Catalonia) were the basins with lowest ∑PECriver (between 0.2 and 3.3 μg L−1), due to either high DF values (Table 1) and/or low population. Contrarily, Francolí and Besòs were the basins with the highest ∑PECriver with 50.3 and 66.6 μg L−1, respectively, as these two rivers have the lowest DF of all of them (see Table 1) and, in the case of Besòs river, it is characterized by highly urbanized area. The high variability in the Llobregat river flow (see Table 1) report high ∑PECriver in the time with low flows and lower ∑PECriver values in the time with highest flows (Table 3).

Table 3. PECriver (μg L−1) ranges in each river basin for the 6 pharmaceuticals with the highest PECs. Mean represents PEC values calculated with mean DF, and min and max represent PEC values calculated with high and low DF, respectively (values given in Table 1). Due to the different excretion and WWTP removals, the values of gabapentin and pentoxifylline are similar.

Hydrographic basins Metformin Amoxicillin Metamizol Levetiracetam Gabapentin Pentoxifylline

Mean (min-max) Mean (min-max) Mean (min-max) Mean (min-max) Mean (min-max) Mean (min-max)

Muga 2.4 (1.3–26.9) 2.0 (1.0–21.7) 0.8 (0.4–8.6) 0.4 (0.2–4.5) 0.3 (0.1–3.0) 0.3 (0.1–3.0)

Fluvià 0.8 (0.5–5.2) 0.7 (0.4–4.2) 0.3 (0.2–1.7) 0.1 (0.09–0.9) 0.09 (0.06–0.6) 0.09 (0.06–0.6)

Ter 2.3 (1.8–8.2) 1.8 (1.4–6.6) 0.7 (0.6–2.6) 0.4 (0.3–1.4) 0.3 (0.2–0.9) 0.25 (0.2–0.9)

Tordera 2.7 (1.5–13.9) 2.2 (1.2–11.2) 0.9 (0.5–4.4) 0.5 (0.2–2.3) 0.3 (0.2–1.5) 0.3 (0.2–1.5)

Besòs 26.5 (7.6–1061) 21.3 (6.1–853) 8.5 (2.4–339) 4.5 (1.3–179) 2.9 (0.8–118) 2.9 (0.8–117)

Llobregat 7.4 (0.5–496) 6.0 (0.4–399) 2.4 (0.2–158) 1.2 (0.1–84) 0.8 (0.05–55) 0.8 (0.05–54.8)

Francolí 20.0 (4.5–181) 16.1 (3.6–145) 6.4 (1.4–58) 3.4 (0.8–30.4) 2.2 (0.5–20.1) 2.2 (0.5–19.9)

Ebre 0.08 (0.07–0.09) 0.06 (0.05–0.07) 0.03 (0.02–0.03) 0.013 (0.011–0.15) 0.009 (0.008–0.01) 0.009 (0.008–0.01)

Segre 1.3 (1.0–1.8) 1.1 (0.8–1.4) 0.4 (0.3–0.6) 0.2 (0.2–0.3) 0.15 (0.1–0.2) 0.15 (0.1–0.2)

Noguera Pallaresa 0.12 (0.10–0.13) 0.1 (0.08–0.11) 0.04 (0.03–0.04) 0.02 (0.016–0.022) 0.013 (0.011–0.014) 0.013 (0.01–0.015)

Noguera Ribagorçana 0.8 (0.6–0.9) 0.6 (0.5–0.7) 0.25 (0.2–0.3) 0.13 (0.010–0.015) 0.09 (0.07–0.10) 0.085 (0.07–0.10)

Fig. 3. ∑PECriver of pharmaceuticals in the main hydrographic basins of Catalonia in 2016.

Table SI4 displays all PECriver values for all pharmaceuticals in each hydrographic basin in Catalonia considering the mean DF, and minimum and maximum DFs. In Besòs, Francolí and Llobregat rivers, >90% of the pharmaceuticals compiled had PECriver values higher 0.010 μg L−1, which is the EMA proposed threshold (EMA, 2006). However, in the rest of rivers studied, <47% of the pharmaceuticals had PECriver values higher 0.010 μg L−1. Even so, the levels of PECs reported in the present study are higher in comparison to the predicted environmental concentrations of pharmaceuticals in different studies (Burns et al., 2018; Franquet-Griell et al., 2015; Franquet-Griell et al., 2017; Verlicchi et al., 2014). For instance, in Besòs and Francolí, the most impacted river basins in Catalonia, metformin and amoxicillin had a PECriver of 26.5 and 21.3 μg L−1 in Besòs basin, and 20.0 and 16.1 μg L−1 in Francolí basin (in 2016). Following, metamizole had 8.5 and 6.4 μg L−1, levetiracetam 4.5 and 3.4 μg L−1, gabapentin 2.9 and 2.2 μg L−1 and pentoxifylline acid 2.9 and 2.2 μg L−1 respectively for the two basins (Table 3). On the other hand, Nogueres and Ebro, which accounted for the lowest impacted basins, PECriver for metformin was of 0.8–0.12 and 0.08 μg L−1 respectively, much lower than values predicted in the other basins. Recently, Lindim et al. (2016) evaluated the emissions and concentrations of 54 pharmaceuticals in Swedish river basins, reporting that metformin, gabapentin and atenolol were the pharmaceuticals with the highest emissions. The prioritized pharmaceuticals for monitoring (metformin, amoxicillin, metamizole, levetiracetam, gabapentin and pentoxifylline) would always be detected in low river flow conditions (low values of DF). In this scenario, Llobregat would also be impacted by high concentrations of pharmaceuticals whereas in Muga, Fluvià, Ter, Tordera, Ebro, Segre and Nogueres the PECriver values would be lower (Tables 3 and SI4). Thus, because the studied rivers have high variable flow, the use of specific DFs which consider the seasonal variability of water flows can provide a better characterization of the presence of pharmaceuticals in a specific river basin and thus, a more accurate risk assessment.

3.4. Environmental risk assessment (ERA) of pharmaceuticals: the case study of Catalonia

For the six pharmaceuticals having the highest PECs, we calculated the environmental risks using the worst river scenario (Besòs river), which has the lowest dilution factor of the studied rivers and hence the highest PECs. We also included paracetamol, ibuprofen and acetylsalicylic acid due to their highly prescription rate and usage in Spain. Reported concentration effects from acute and chronic toxicity studies for at least three different aquatic phyla were considered (i.e. algae or plant, vertebrate, invertebrate) to estimate predicted non-effect concentrations (PNECs). Assessment factors of 10 and 1000 were used to determine PNECs from chronic and acute concentration effects, respectively. Toxicity data was obtained from toxicological databases (DrugBank, EPA), chemical suppliers (Sigma-Aldrich) and selected publications and experimental test for metformin. When more than one concentration effect was reported within a given toxicity source, chemical and species, its median was considered. Environmental risks were obtained using the risk quotient approach depicted in Eq. (4). Results reported in Table 4 reflect the reported known scarcity for chronic toxicity data on pharmaceuticals, which in most cases was limited to a single species (Fent et al., 2006a). For three chemicals, levetiracetam, gabapentin and pentoxifylline there was no toxicological information and for metamizole, toxicological information was limited to a single study. Table 4 also evidenced the great disparity of toxicological information within and among species, which in several cases expanded several orders of magnitude (Santos et al., 2010). For the antibiotic amoxicillin cyanobacteria species were about three orders of magnitude more sensitive than the rest of species, which is in line with previous studies (Andreozzi et al., 2004). Paracetamol acute toxicity data was the most variable within a given species (over 4 orders of magnitude for Danio rerio LC50) and ibuprofen showed the greatest differences between acute and chronic toxicity responses (350 fold in Danio rerio) and among algae species (85 fold). Disparity of results within species for metformin and acetylsalicylic acid were within an order of magnitude. When outlier values from Table 4 were not considered, Daphnia and algae species were about 10 fold more sensitive than fish to paracetamol and acetylsalicylic acid and fish were up to 300 fold more sensitive to metformin and ibuprofen than Daphnia and algae. The above mentioned lack of consistence in species sensitivity across the studied pharmaceuticals agrees with previous reported toxicological information (Santos et al., 2010) but partly disagrees with the argument claiming that pharmaceuticals should affect to greater extent fish than algae or invertebrates due to the presence of more biological targets in fish (Fent et al., 2006a; Gunnarsson et al., 2008).

Table 4. Acute and chronic toxicity and risk assessment for pharmaceuticals in Besòs River (2016, calculated with the mean flow) for pharmaceuticals with PECriver > 0.1 μg L−1 indicate in Table 2 and include also paracetamol, ibuprofen and acetylsalicylic acid which are highly consumed despite having low PECs. RQ: Risk Quotient based on an assessment factor of 1000 except for \* which as 10 (OECD, 2002).

ATC code Name PECriver

Besòs (2016) (mg L−1) Organism Specie End-point Response Reference EC50/LC50

(mg L−1) PNEC RQ

N02BE01 Paracetamol 1.1e−4 Algae Not indicated Not indicated Growth (Osorio et al., 2016) 134 0.13 0.0009

Crustacean D. magna EC50 48 h Mortality (S. Aldrich, 2016a) 9.2 0.01 0.0114

D. magna LC50 (96 h) Mortality (Iannacone and Alvariño, 2009) 62.3 0.06 0.0019

D. magna NOEC Reproduction (E.P.A. (EPA), 2018) 5.7 0.57\* 0.00020

Fish P. promelas EC50 (96 h) Mortality (S. Aldrich, 2016a) 814 0.81 0.00014

O. latipes LC50 (96 h) Mortality (S. Aldrich, 2016a) 160 0.16 0.00071

D. rerio EC50 (168 h) Mortality (Osorio et al., 2016) 0.01 0.00001 11.43

A10BA02 Metformin 0.026 Aquatic plant Lemmna EC50 (7d) Growth (Cleuvers, 2003) 110 0.11 0.241

Crustacean D. magna LC50 (48 h) Mortality Present study 16.9 0.02 1.325

D. magna LC50 (48 h) Mortality (Cleuvers, 2003) 64 0.06 0.442

Fish Fathead minnows LOEC Endocrine disruption (Niemuth et al., 2015) 0.4 0.04\* 0.663

Pimephales promelas LOEC Reproduction (Niemuth and Klaper, 2015) 0.04 0.004\* 6.625

J01CA04 Amoxicillin 0.021 Algae M. aeruginosa EC50 Mortality (Lützhøft et al., 1999) 0.0037 0.000004 5325

R. salina EC50 Mortality (Lützhøft et al., 1999) 3.108 0.003 7.1

S. capricornutum EC50 Mortality (Lützhøft et al., 1999) 250 0.25 0.0852

Fish D. rerio EC50 (48 h) Mortality (Oliveira et al., 2013) 132.4 0.13 0.164

O. latipes LC50 (48 h) Mortality (Park and Choi, 2008) >1000 1 0.0213

Crustacean D. magna LC50 (96 h) Mortality (Iannacone and Alvariño, 2009) 6950 6.95 0.0031

N02BB02 Metamizole 0.0085 Fish Rhamdia quelen LOEC DNA damage (Pamplona et al., 2011) 0.0005 0.00005\* 170

M01AE01 Ibuprofen 5.8e−4 Algae Not indicated Not indicated Mortality (Osorio et al., 2016) 4 0.004 0.1178

D. subspicatus EC50\* Mortality (Cleuvers, 2003) 342.2 0.34 0.0014

Crustacean D. magna LC50 (96 h) Mortality (Iannacone and Alvariño, 2009) 175 0.18 0.0026

D. magna LC50 (48 h) Mortality (Cleuvers, 2003) 101.2 0.1 0.0047

Fish D. rerio LC50 (96 h) Mortality (E.P.A. (EPA), 2018) 0.35 0.0004 1.18

D. rerio LC50 (7d) Mortality (E.P.A. (EPA), 2018) 0.001 0.0001\* 4.71

B01AC06 Acetylsalicylic acid 4.7e−4 Algae D. subspicatus EC50 (72 h) Growth (Cleuvers, 2003) 106.7 0.11 0.0053

Fish Cyprinus carpio LC50 (48 h) Mortality (S. Aldrich, 2016b) 1000 1 0.0006

Crustacean D. magna EC50 (48 h) Mortality (Cleuvers, 2003) 88.1 0.09 0.0064

Cnidiaria Hydra sp LOEC Viability (E.P.A. (EPA), 2018) 1 0.1\* 0.0058

N03AX14 Levetiracetam 4.5e−3 Not data Not data – – – – – –

N03AX14 Gabapentin 2.9e−3 Fish D. rerio LOEC Malformation (Li et al., 2018) 0.1 0.01\* 0.29

C04AD03 Pentoxifylline 2.9e−3 Not data Not data – – – – – –

Estimated risks reported in Table 4 showed the same high variability within and among species and chemicals than PNEC. Thus to properly prioritize environmental risks of the studied compounds we excluded out the extreme values for ibuprofen (RQ = 4.71), paracetamol (RQ = 11.43), metformin (RQ = 6.22) and amoxicillin (RQ = 5325). Except for metamizole and gabapentin, whose high risk quotients (170 and 0.29, respectively) were based on a single study, the compound having the greatest risks to aquatic biota was amoxicillin (average ± SE, RQ = 1.47 ± 1.40) followed by decreasing order by metformin (0.66 ± 0.21), ibuprofen (0.26 ± 0.23), acetylsalicylic acid (0.004 ± 0.001) and paracetamol (0.002 ± 0.002). For amoxicillin, metformin and ibuprofen predicted risks exceeded for some species. Therefore, environmental risk assessment data depicted in Table 4 allowed identifying key features among the prioritized 5 pharmaceuticals with at least three RQ. Amoxicillin is expected to pose adverse effects for cyanobacteria, and metformin and ibuprofen pose a small potential for adverse effects to invertebrates and fish, and fish, respectively. Alternatively, paracetamol and acetylsalicylic acid posed no risk to aquatic biota.

As a final remark it is important to take into account that in this study we based our prioritization on PECs and not on toxicity. For example, among the 43 compounds depicted in Table 2 disulfiram followed by fluoxetine, lithium and diclofenac were quite toxic having EC50 for zebrafish embryonic development or D. magna immobilization of (Mean ± SE): 0.027 ± 0.013 mg L−1 for disulfiram, 0.399 ± 0.104 mg L−1 for fluoxetine, 3.340 ± 1.274 mg L−1 for lithium and 4.752 ± 1.248 mg L−1 for diclofenac (data obtained from E.P.A. (EPA), ECOTOX Knowledgebase). These values are quite low when compared with those reported in Table 4, which means that the above reported compound can also be considered potential toxic to aquatic biota. Future research, thus, should assess if there is a need to prioritize compounds by their toxicity rather than by their PECs.

4. Conclusions

This study reveals the importance of consumption data and temporal patterns for estimating the occurrence and risk of pharmaceuticals consumed by elderly people in surface waters. An extensive data compilation on pharmaceuticals consumption in Catalonia was performed. The mean total consumption of these pharmaceuticals in the period studied (2013–2016) was 623 ± 3 t per year. ATC groups N (nervous system), A (alimentary tract and metabolism) and M (musculo-skeletal system) showed the highest consumptions, being paracetamol, metformin and ibuprofen the top consumed. However, metformin, amoxicillin, metamizole, were the pharmaceuticals with highest PEC values (>0.01 μg L−1). In addition, recalculation of PECs according to specific river dilution factors permits to refine the levels likely to be detected at river basin scale. It is clear from this study that PEC calculation permits to better prioritize compounds, which have high probability to be detected in the environment. Finally, predicted environmental levels together with acute and chronic toxicological data allowed estimating the risks of these compounds. Amoxicillin is expected to pose adverse effects for cyanobacteria, and metformin and ibuprofen pose a small potential for adverse effects to invertebrates and fish, and fish, respectively. Alternatively, paracetamol and acetylsalicylic acid posed no risk to aquatic biota.